Pfizer is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to combat a potential slowdown in COVID products demand as cases fall.
Suscribirse a:
Enviar comentarios (Atom)
Comentarios
Publicar un comentario
Leave a comment. Thanks!
Comentarios de Facebook